AtriCure, Inc. (ATRC)

AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year....

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...

Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year....

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000....

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the posit...

Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year....

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...

Campbell and CO Investment Adviser LLC purchased a new stake in AtriCure, Inc. (NASDAQ: ATRC) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional invest...

AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director C...

The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...